This afternoon we watched ResMed rise 3.2% to a price of $141.88 per share. The large-cap Medical Instruments & Supplies company is now trading -22.89% below its average target price of $184.0. Analysts have set target prices ranging from $165.0 to $220.0 per share for ResMed, and have given the stock an average rating of buy.
ResMed's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 3.8%. The stock's short ratio is 2.7. The company's insiders own 1.3% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 66.8%. In conclusion, we believe there is positive market sentiment regarding ResMed.
Institutions Invested in ResMed
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-06-30 | Vanguard Group Inc | 12% | 17,576,623 | $2,493,771,357 |
| 2023-06-30 | Blackrock Inc. | 8% | 12,236,592 | $1,736,127,732 |
| 2023-06-30 | State Street Corporation | 4% | 6,388,113 | $906,345,503 |
| 2023-06-30 | FMR, LLC | 4% | 6,094,608 | $864,703,012 |
| 2023-06-30 | Geode Capital Management, LLC | 2% | 3,328,725 | $472,279,519 |
| 2023-06-30 | Capital World Investors | 2% | 2,357,117 | $334,427,771 |
| 2023-06-30 | Invesco Ltd. | 1% | 2,100,905 | $298,076,411 |
| 2023-06-30 | Citadel Advisors Llc | 1% | 1,859,073 | $263,765,286 |
| 2023-06-30 | Northern Trust Corporation | 1% | 1,615,725 | $229,239,070 |
| 2023-06-30 | Ownership Capital B.V. | 1% | 1,508,014 | $213,957,033 |
